Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Lentiviral delivery of combinatorial CAR/CRISPRi circuit into human primary T cells is enhanced by TBK1/IKKɛ complex inhibitor BX795

Fig. 3

Effect of BX795 treatment on RB-340-1F transduction of CD4+ T cells and CD8+ T cells. a Percentage of CD4+ cells and percentage of CD8+ cells in the bulk population on day 6 before cell sorting. b Percentage of double transduced cells in CD4+ or CD8+ cells on day 6. BX795-: no BX795 treatment. BX795+ : with BX795 treatment. The above results are the average of four donors. c Percentage of CD4+ cells in double transduced cells on day 6 and day 13. d Percentage of CD8+ cells in double transduced cells on day 6 and day 13. BX795-: no BX795 treatment. BX795+ : with BX795 treatment. The above results are the average of three donors. *p < 0.05; **p < 0.01

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us